Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The GABA-A receptor containing α1β2γ2 subunits is the most abundant isoform of the gamma-aminobutyric acid type A receptor in the mammalian central nervous system, accounting for approximately 60% of all GABA-A receptors (Guide to Pharmacology, 2023). It is a pentameric ligand-gated ion channel composed of two α1, two β2, and one γ2 subunit arranged around a central chloride-selective pore (Wikipedia, 2024). This receptor subtype mediates fast inhibitory synaptic transmission, also known as phasic inhibition, by allowing chloride ions to flow into the neuron upon GABA binding, leading to membrane hyperpolarization (StatPearls, 2023). It is the primary target for several classes of clinically important drugs, including benzodiazepines, which bind at the α1/γ2 interface to enhance the receptor's response to GABA (PubMed, 2021). Due to its widespread distribution in the brain, particularly in the cerebral cortex and hippocampus, it plays a critical role in regulating neuronal excitability and is a key therapeutic target for treating anxiety, insomnia, and epilepsy (NIH, 2022). Dysfunction of this receptor is implicated in various neurological and psychiatric conditions, including epilepsy and alcohol use disorders (Frontiers in Pharmacology, 2020). Chronic modulation of this receptor can lead to significant safety concerns such as tolerance, physical dependence, and cognitive side effects (Mayo Clinic, 2023). Additionally, it is sensitive to non-benzodiazepine hypnotics like zolpidem, which show high affinity for the α1 subunit (PubChem, 2024). The receptor's activity is also modulated by barbiturates, neurosteroids, and certain general anesthetics, which act at distinct allosteric sites (UniProt, 2024). Overall, the α1β2γ2 GABA-A receptor is a fundamental component of inhibitory signaling in the brain and a cornerstone of neuropsychopharmacology.
Positive allosteric modulation of the GABA-A receptor chloride channel, primarily by increasing the frequency of channel opening in response to GABA binding at the alpha-beta interface.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid type A receptor alpha-1 beta-2 gamma-2 subtype (GABA-A receptor alpha1beta2gamma2) (GABA-A receptor α1β2γ2).